Tradestie Institutional Equity Comparison Engine

ANRO vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, ANRO sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner CVM
ANRO N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner ANRO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -62.7%
Momentum & Technical Winner ANRO
1Y +105.7% vs -73.8% ยท 52W Pos 53% vs 14%
Options & Structure Winner ANRO
BREAKDOWN (9th %ile IV) vs BREAKDOWN (N/A IV)
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$24.91
-8.15% 1D
Market Cap $1.2B
1M Return +9.16%
1Y Return +105.7%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap $22.5M
1M Return +12.12%
1Y Return -73.76%
Forward P/E 23.0x
Unified AI Score
43.5 / 100 HOLD
Tech 23.0 Fund 47.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANRO +105.7% CVM -73.76% Spread: +177.75 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANRO TTM Op. Margin: 0.0% CVM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs CVM. Trailing 12-month operating profitability (ANRO 0.0% vs CVM 0.0%) and valuation multiples (ANRO N/M vs CVM 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANRO (5) vs CVM (3)
Institutional Metric ANRO CVM Criterion Row Winner
Market Capitalization Scale $1.2B $22.5M Larger Scale ANRO
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY) Growth +0.0% -62.7% Higher Growth ANRO
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -46.7% -252.5% Higher ROE ANRO
52-Week Range Position Momentum 53% ($11โ€“$37) 14% ($1โ€“$8) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 2.03ฮฒ ยท 94% Vol 0.42ฮฒ ยท 140% Vol Lower Realized Risk ANRO
Unified Institutional Score Composite Signal 34.3 / 100 (SELL) 43.5 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANRO vs CVM Buy Guide
ANRO BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANRO nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.